Nucleic acid therapeutics for hematologic malignancies--theoretical considerations
2006 (English)In: OLIGONUCLEOTIDE THERAPEUTICS / [ed] Tuschl T; Rossi J, 2006, Vol. 1082, 124-136 p.Conference paper (Refereed)
Our work is motivated by the belief that RNA targeted gene silencing agents can be developed into effective drugs for treating hematologic malignancies. In many experimental systems, antisense nucleic acids of various composition, including antisense oligodeoxynucleotides (AS ODNs) and short interfering RNA (siRNA), have been shown to perturb gene expression in a sequence specific manner. Nevertheless, our clinical experience, and those of others, have led us to conclude that the antisense nucleic acids (ASNAs) we, and others, employ need to be optimized with regard to intracellular delivery, targeting, chemical composition, and efficiency of mRNA destruction. We have hypothesized that addressing these critical issues will lead to the development of practical and effective nucleic acid drugs. An overview of our recent work which seeks to addresses these core issues is contained within this review.
Place, publisher, year, edition, pages
2006. Vol. 1082, 124-136 p.
, Annals of the New York Academy of Sciences, ISSN 0077-8923 ; 1082
leukemia, lymphoma, antisense, oligonucleotides
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-22692DOI: 10.1196/annals.1348.002ISI: 000243449900017PubMedID: 17145934ISBN: 978-157331587-6OAI: oai:DiVA.org:uu-22692DiVA: diva2:50465
1st Annual Meeting of the Oligonucleotide-Therapeutics-Society New York, NY, 2005